{
  "id": "mhgap#risk_safety_f645292d",
  "content": "2020 (71 RCTs) (77).\nResearch gaps\ny The available evidence on pharmacological\ny Additional evidence on the use of pharmacological\ninterventions for depression in children under 12\ninterventions in children is required, with due\nis very limited.\nattention to monitoring adverse effects and risk\ny SSRI use is associated with an increased risk\nof overmedicalization.\nof suicide and suicide attempts (78). Since the\nharms of the intervention outweigh the benefits,\nImplementation considerations\na strong recommendation is made against use of\ny Access to psychotherapy, particularly cognitive\nantidepressants for treatment of depression in\nbehavioural interventions and caregiver\nchildren 12 years of age or younger.\nskills training, in line with other mhGAP\nrecommendations, remains important for\nRemarks\nchildren with moderate-to-severe depression and\ny Diagnosis of depression in children can be\ntheir caregivers.\ninfluenced by the cultural context and requires a\nRecommendation (new): 4.3 If psychosocial interventions alone prove ineffective in adolescents\n(13–17 years) with moderate-to-severe depression, referral to or consultation\nwith a specialist should be offered, to undertake a more comprehensive\nassessment and to explore initiation of fluoxetine in combination with\npsychological treatments.\nStrength of recommendation: Strong\nCertainty of evidence: Low\nJustification depressive symptoms and the positive effects of",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety 2020 (71 RCTs) (77).\nResearch gaps\ny The available evidence on pharmacological\ny Additional evidence on the use of pharmacological\ninterventions for depression in children under 12\ninterventions in children is required, with due\nis very limited.\nattention to monitoring adverse effects and risk\ny SSRI use is associated with an increased risk\nof overmedicalization.\nof suicide and suicide attempts (78). Since the\nharms of the intervention outweigh the benefits,\nImplementation considerations\na strong recommendation is made against use of\ny Access to psychotherapy, particularly cognitive\nantidepressants for treatment of depression in\nbehavioural interventions and caregiver\nchildren 12 years of age or younger.\nskills training, in line with other mhGAP\nrecommendations, remains important for\nRemarks\nchildren with moderate-to-severe depression and\ny Diagnosis of depression in children can be\ntheir caregivers.\ninfluenced by the cultural context and requires a\nRecommendation (new): 4.3 If psychosocial interventions alone prove ineffective in adolescents\n(13–17 years) with moderate-to-severe depression, referral to or consultation\nwith a specialist should be offered, to undertake a more comprehensive\nassessment and to explore initiation of fluoxetine in combination with\npsychological treatments.\nStrength of recommendation: Strong\nCertainty of evidence: Low\nJustification depressive symptoms and the positive effects of 2020 (71 rcts) (77). research gaps\ny the available evidence on pharmacological\ny additional evidence on the use of pharmacological\ninterventions for trầm cảm in children under 12\ninterventions in children is required, wi..."
}